Alan K. Hatfield

5.9k total citations · 2 hit papers
55 papers, 4.4k citations indexed

About

Alan K. Hatfield is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alan K. Hatfield has authored 55 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 10 papers in Molecular Biology. Recurrent topics in Alan K. Hatfield's work include Cancer Treatment and Pharmacology (9 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Cancer therapeutics and mechanisms (6 papers). Alan K. Hatfield is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Cancer therapeutics and mechanisms (6 papers). Alan K. Hatfield collaborates with scholars based in United States, United Kingdom and Switzerland. Alan K. Hatfield's co-authors include Ronald H. Blum, René Gonin, Charles S. Cleeland, John H. Edmonson, Kishan J. Pandya, James A. Stewart, Charles L. Loprinzi, Jörge E. Cortes, William H. Redd and Michael A. Andrykowski and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Alan K. Hatfield

54 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pain and Its Treatment in Outpatients with Metastatic Cancer

1994 1.6k citations Charles S. Cleeland, René Gonin et al. New England Journal of Medicine profile →
International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

2009 444 citations Alan K. Hatfield, Insa Gathmann et al. profile →

Peers

Countries citing papers authored by Alan K. Hatfield

Since Specialization

Citations

This map shows the geographic impact of Alan K. Hatfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan K. Hatfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan K. Hatfield more than expected).

Fields of papers citing papers by Alan K. Hatfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan K. Hatfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan K. Hatfield. The network helps show where Alan K. Hatfield may publish in the future.

Co-authorship network of co-authors of Alan K. Hatfield

This figure shows the co-authorship network connecting the top 25 collaborators of Alan K. Hatfield. A scholar is included among the top collaborators of Alan K. Hatfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan K. Hatfield. Alan K. Hatfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias 2008 ·Annals of Oncology ·Renaud Capdeville, Tillmann Krahnke, Alan K. Hatfield, J. Ford, (unknown), Insa Gathmann	12
2	Treatment Interruptions and Non-Adherence with Imatinib and Associated Healthcare Costs 2007 ·PharmacoEconomics ·Theodore Darkow, Henry J. Henk, Simu K. Thomas, Weiwei Feng, Jean‐François Baladi, George A. Goldberg, Alan K. Hatfield, Jörge E. Cortes	233
3	Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer 2004 ·Lung Cancer ·Edith A. Perez, Francois J. Geoffroy, Shauna Hillman, Elizabeth A. Johnson, Gist H. Farr, (unknown), Alan K. Hatfield, James E. Krook, (unknown), Ralph Levitt, Randolph S. Marks	10
4	Alternating chemotherapy with etoposide plus cisplatin and topotecan plus paclitaxel in patients with untreated, extensive‐stage small cell lung carcinoma 2003 ·Cancer ·James R. Jett, Alan K. Hatfield, Shauna L. Hillman, (unknown), James A. Mailliard, John W. Kugler, Roscoe F. Morton, Randolph S. Marks, Ralph Levitt	17
5	Long-Term Survival of Patients With Advanced/Recurrent Carcinoma of Cervix and Vagina After Neoadjuvant Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without the Addition of Molgramostim, and Review of the Literature 2002 ·American Journal of Clinical Oncology ·Harry J. Long, (unknown), Karl C. Podratz, (unknown), Vera J. Suman, Lynn C. Hartmann, Ralph Levitt, Suresh Nair, Alan K. Hatfield, James A. Knost	12
6	Prediction of Node-Negative Breast Cancer Outcome by Histologic Grading and S-Phase Analysis by Flow Cytometry 2001 ·American Journal of Clinical Oncology ·David L. Page, Robert P. Gray, D. Craig Allred, Lynn G. Dressler, Alan K. Hatfield, Silvana Martino, Nicholas J. Robert, William C. Wood	43
7	A phase II study of paclitaxel plus carboplatin as first‐line chemotherapy for women with metastatic breast carcinoma 2000 ·Cancer ·Edith A. Perez, David W. Hillman, Philip J. Stella, James E. Krook, Lynn C. Hartmann, Tom R. Fitch, Alan K. Hatfield, James A. Mailliard, Suresh Nair, Carl G. Kardinal, James N. Ingle	13
8	A Randomized Phase II and Pharmacokinetic Study of Dacarbazine in Patients with Recurrent Glioma 2000 ·Journal of Neuro-Oncology ·S. Vincent Rajkumar, Joel M. Reid, Paul J. Novotny, Stephanie L. Safgren, Bernd W. Scheithauer, Patrick S. Johnson, Suresh Nair, Roscoe F. Morton, Alan K. Hatfield, James E. Krook, Matthew M. Ames, Jan C. Buckner	8
9	A Phase II Study of High-Dose Cimetidine and the Combination 5-Fluorouracil, Interferon Alpha-2A, and Leucovorin in Advanced Renal Cell Adenocarcinoma 1998 ·American Journal of Clinical Oncology ·Edward T. Creagan, Michael H. Veeder, Vera J. Suman, Patrick A. Burch, William J. Maples, Paul Schaefer, Delano M. Pfeifle, Robert J. Dalton, Alan K. Hatfield, Michael A. Poon	3
10	Prospectively randomized North Central Cancer Treatment Group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer. 1997 ·Journal of Clinical Oncology ·Robert M. Goldberg, Alan K. Hatfield, Michael Kahn, Daniel J. Sargent, James A. Knost, M J O'Connell, James E. Krook, (unknown), Martin Wiesenfeld, (unknown), Maria Tria Tirona, C G Moertel	35
11	Pilot study evaluating local anesthetics administered systemically for treatment of pain in patients with advanced cancer 1997 ·Journal of Pain and Symptom Management ·(unknown), Mary E. Bretscher, James A. Mailliard, Loren K. Tschetter, David W. Kimmel, Alan K. Hatfield, Charles L. Loprinzi	15
12	A randomized Phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma 1997 ·Cancer ·James N. Ingle, Patricia Johnson, Vera J. Suman, James B. Gerstner, James A. Mailliard, John Camoriano, Dean H. Gesme, Charles L. Loprinzi, Alan K. Hatfield, Lynn C. Hartmann	52
13	Octreotide as first-line treatment for women with metastatic breast cancer 1996 ·Investigational New Drugs ·(unknown), Carl G. Kardinal, Vera J. Suman, James E. Krook, Alan K. Hatfield	18
14	Megestrol Acetate for the Prevention of Hot Flashes 1995 ·Obstetrical & Gynecological Survey ·Charles L. Loprinzi, John C. Michalak, Susan K. Quella, Judith R. OʼFallon, Alan K. Hatfield, Robert A. Nelimark, Ann Marie Dose, Tammy Fischer, (unknown), (unknown), (unknown), Raylene M. Rospond, Joseph E. Oesterling	6
15	Phase III Evaluation of 4 Doses of Megestrol Acetate as Therapy for Patients with Cancer Anorexia and/or Cachexia 1994 ·Oncology ·(unknown), Albert M. Bernath, Daniel J. Schaid, (unknown), (unknown), John C. Michalak, Loren K. Tschetter, Alan K. Hatfield, Roscoe F. Morton	44
16	Megestrol Acetate for the Prevention of Hot Flashes 1994 ·New England Journal of Medicine ·Charles L. Loprinzi, John C. Michalak, Susan K. Quella, Judith R. OʼFallon, Alan K. Hatfield, Robert A. Nelimark, Ann Marie Dose, Tammy Fischer, (unknown), (unknown), (unknown), Raylene M. Rospond, Joseph E. Oesterling	371
17	Pain and Its Treatment in Outpatients with Metastatic Cancer breakdown → 1994 ·New England Journal of Medicine ·Charles S. Cleeland, René Gonin, Alan K. Hatfield, John H. Edmonson, Ronald H. Blum, James A. Stewart, Kishan J. Pandya	1597
18	Correlation of acute lethal potency with in vitro cytotoxicity 1990 ·Toxicology in Vitro ·Jeffrey R. Fry, M.J. Garle, Alison H. Hammond, Alan K. Hatfield	27
19	Cancer Patients and Their Co-Workers 1988 ·Social Work in Health Care ·(unknown), Jill Doner Kagle, Alan K. Hatfield	7
20	Development of anticipatory nausea: A prospective analysis. 1985 ·Journal of Consulting and Clinical Psychology ·Michael A. Andrykowski, William H. Redd, Alan K. Hatfield	97

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact